Medigene AG (ETR:MDG1 – Get Free Report)’s share price fell 1.2% during mid-day trading on Thursday . The company traded as low as €2.12 ($2.35) and last traded at €2.12 ($2.35). 2,742 shares traded hands during trading, a decline of 99% from the average session volume of 306,207 shares. The stock had previously closed at €2.14 ($2.38).
Medigene Trading Up 0.9 %
The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.94. The stock has a market cap of $31.47 million, a P/E ratio of -1.75, a PEG ratio of 7.12 and a beta of 0.84. The firm’s 50-day simple moving average is €1.55 and its 200 day simple moving average is €1.52.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Read More
- Five stocks we like better than Medigene
- Following Congress Stock Trades
- When Is the Best Time to Invest in Mutual Funds?
- Business Services Stocks Investing
- Is NVIDIA Stock in a Correction or Consolidation?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.